Torsdag 19 Juni | 14:23:43 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-25 08:00 Bokslutskommuniké 2025
2025-11-27 08:00 Kvartalsrapport 2025-Q3
2025-08-27 08:00 Kvartalsrapport 2025-Q2
2025-05-27 - Kvartalsrapport 2025-Q1
2025-05-19 - Årsstämma
2025-02-26 - Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-29 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning GEAN 0.00 NOK
2024-05-14 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-20 - Extra Bolagsstämma 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-05-12 - X-dag ordinarie utdelning GEAN 0.00 NOK
2023-05-11 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-13 - Kvartalsrapport 2022-Q1
2022-04-29 - X-dag ordinarie utdelning GEAN 0.00 NOK
2022-04-28 - Årsstämma
2022-02-18 - Bokslutskommuniké 2021
2021-11-09 - Kvartalsrapport 2021-Q3
2021-09-20 - Extra Bolagsstämma 2021

Beskrivning

LandNorge
Lista12
SektorHälsovård
IndustriBioteknik
Genetic Analysis är verksamma inom medicinteknik. Bolaget bedriver forskning och utveckling inom området för diagnostik, med störst fokus mot mänsklig mikrobiomet. Tekniken utgår ifrån bolagets forskningsplattform och IVD-produkterna används exempelvis för testtagning och analys av bakterier och virus. Störst verksamhet återfinns inom den nordiska marknaden och produkterna vidaresäljs huvudsakligen till laboratorier. Bolaget har sitt huvudkontor i Oslo, Norge.
2025-05-27 08:56:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW.

OSLO, NORWAY - May 27, 2025
: Genetic Analysis AS ("GA" or the "Company") today announces further details regarding the Subsequent Offering of shares, following the Directed Issue of shares approved at the Company's Annual General Meeting (AGM) on May 19, 2025.

As previously communicated in our press release on May 5, 2025, the Board of Directors has now decided to proceed with the Subsequent Offering. The offering will be structured so that six (6) existing shares will entitle the holder to subscribe for one (1) new share, at a subscription price of NOK 0.86 per share.

As stated in our press release on May 5th, the Board intended to conduct a Subsequent Issue of shares related to the Directed Issue of shares approved on the Company's' Annual General Meeting on 19 May.

The Board has decided to proceed with an offering in which shareholders will have the right to subscribe for one new share for every six (6) existing shares held, at a subscription price of NOK 0.86 per share. Tradeable subscription rights will be issued to all shareholders registered in Euronext VPS on the record date 2 June 2025. Each existing share will grant one subscription right and six (6) subscription rights give the right to subscribe for one (1) new share.

The shares will therefore trade ex subscription rights as from 3 June 2025. New shares approved in the Annual General Meeting but not yet formally issued will not obtain subscription rights. The subscription rights will be tradeable on Spotlight Stock Market from 5 June to 12 June. The last day for subscriptions will be 16 June. Oversubscriptions will be allowed.

If fully subscribed, the issue will be for NOK 7.1 million and will, after cost contribute some NOK 6.0 million to the capital base of the Company. The purpose of the issue is also to provide shareholders, who were not invited to participate in the Directed Issue, with an opportunity to subscribe for additional shares in the Company.

An Exemption document containing complete terms and conditions for the Subsequent Offering is expected to be published around June 2, 2025.

In connection with the Subsequent Offering, Sedermera Corporate Finance AB (www.sedermera.se) is appointed Swedish financial advisor.  

As mentioned in our previous press releases the board of directors reserves the right at its sole discretion to decide not to proceed with, or to cancel, the Subsequent Offering.